Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Chemotherapy (CT) + Tyrosine kinase inhibitors (TKIs) & Pancreatic ductal adenocarcinoma (PDAC) / Pancreatic cancer

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

The combination of Chemotherapy (CT) + Tyrosine kinase inhibitors (TKIs) has been studied extensively in Pancreatic ductal adenocarcinoma (PDAC) / Pancreatic cancer, but outside a small benefit with erlotinib + gemcitabine, most TKI-chemotherapy combinations have not produced clinically meaningful gains in unselected pancreatic cancer populations.
Moore et al., 2007

…

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Moore et al., 2007

7/1/2026